GlassScriptPhysician profile
Louis G Molinari
NPI 1093833204
$11,309.24
in general payments reported to CMS, 2019-2025
40 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $933 · 2021: $1,537 · 2022: $2,437 · 2023: $2,221 · 2024: $1,873 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,667 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,667.11 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,510.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,230.11 | 2019-2025 | Breztri, Airsupra, Symbicort |
| Abbvie INC. | $1,032.19 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $861.52 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.24 | 2019-2025 | Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $472.42 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $391.24 | 2019-2024 | Yupelri, Yupelri |
| Electromed, INC. | $388.19 | 2019-2025 | Smartvest |
| Pfizer INC. | $343.27 | 2023-2025 | |
| Insmed, INC. | $334.54 | 2023-2025 | Arikayce, Brinsupri |
| Bayer Healthcare Pharmaceuticals INC. | $247.24 | 2022 | |
| Krystal Biotech INC | $245.10 | 2024-2025 | Vyjuvek |
| Philips North America LLC | $244.06 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Amarin Pharma, INC. | $231.81 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $198.22 | 2023-2025 | Nuzyra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $176.38 | 2019-2024 | Ozempic |
| Mallinckrodt Hospital Products INC. | $170.89 | 2021-2022 | |
| Amgen INC. | $165.53 | 2022-2025 | Tezspire |
| Kowa Pharmaceuticals America, INC. | $146.61 | 2019-2022 | |
| Shield Therapeutics INC | $134.12 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Baxter Healthcare | $122.22 | 2024-2025 | Hillrom - Monarch Airway Clearance System |
| Optinose US, INC. | $117.96 | 2020-2021 | |
| Verona Pharma, INC. | $113.42 | 2025 | Ohtuvayre |
| Strongbridge US INC. | $92.71 | 2020 | |
| Eisai INC. | $92.62 | 2021 | |
| Hikma Pharmaceuticals USA | $69.22 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $55.31 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $54.91 | 2019-2022 | |
| Viatris Specialty LLC | $54.83 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $53.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.63 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.26 | 2022 | |
| Lundbeck LLC | $33.40 | 2025 | Rexulti |
| Gilead Sciences, INC. | $33.15 | 2021 | |
| Pulmonx Corporation | $21.25 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Teva Pharmaceuticals USA, INC. | $19.90 | 2022 | |
| Circassia INC. | $19.87 | 2020 | |
| Phadia US INC. | $17.86 | 2025 | Immunocap |
| Lilly USA, LLC | $17.60 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Molinari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.